Effect of Citicoline on neurodevelopmental outcome of neonates with intraventricular hemorrhage

Evaluating the effect of Citicoline on development of preterm infants with intraventricular hemorrhage admitted in neonatal intensive care units

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20171116037503N3

Enrollment

Registered

2024-09-09

Start date

2024-10-22

Completion date

Unknown

Last updated

2024-09-16

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

neurodevelopmental delay of preterm infant with intraventricular hemorrhage. Delayed milestone in childhood

Interventions

Intervention 1: Intervention group: infants with grade 2 to 4 intraventricular hemorrhage on this ultrasound will be administered intravenous citicoline (Caspian Taamin) at a dose of 10 mg per kilogr

Eligibility

Sex/Gender

All

Age

1 Days to 60 Days

Inclusion criteria

Inclusion criteria: The preterm neonates with gestational age less than 32 weeks or birthweight below 1500 grams Intraventricular hemorrhage grade 2-4

Exclusion criteria

Exclusion criteria: Asphyxia (5th minute Apgar score less than 7, blood gas with PH less than 7 and Base excess less than-16, encephalopathy) Brain structural disease Hyperbilirubinemia needs exchange transfusion Parents refusal for enroll the study

Design outcomes

Primary

Measure	Time frame
Neurodevelopment of infants. Timepoint: 2 months old corrected gestational age. Method of measurement: Age and Stages questionnaire (ASQ).	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactRoya Oboodi

Shiraz University of Medical Sciences

oboodidp@gmail.com+98 71 3612 5000

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026